Apellis Pharmaceuticals, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Product
Licensing and other revenue
Total revenue
Operating expenses:
Cost of sales
Research and development
Selling, general and administrative
Cost of research collaboration
License expense
Total operating expenses:

Net operating income/(loss)
Loss on conversion of debt
Loss on extinguishment of development liability
Loss from remeasurement of development derivative liability
Interest income
Interest expense
Other expense, net
Net income/(loss) before taxes
Income tax expense
Net income/(loss)
Other comprehensive income/(loss):
Unrealized (loss)/gain on marketable securities
Unrealized (loss)/gain on pension plans
Unrealized gain/(loss) on pension plans
Foreign currency translation
Total other comprehensive income/(loss)

Comprehensive income/(loss), net of tax
Net loss per common share, basic and diluted
Weighted-average number of common shares used in net loss per common share, basic and diluted
Net income/(loss) per common share - basic
Net income/(loss) per common share - diluted
Weighted-average number of common shares used in net income/(loss) per common share - basic
Weighted-average number of common shares used in net income/(loss) per common share - diluted

Comments